Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2

Molecular Pharmacology

Volumn 67, Issue 3, 2005, Pages 640-647

  Hata, Aaron N ^a   Lybrand, Terry P ^a   Marnett, Lawrence J ^a,b   Breyer, Richard M ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DESMETHYLINDOMETHACIN; 4 BROMO BENZYL INDOMETHACIN; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; 5' O DESMETHYL INDOMETHACIN; ARYLACETIC ACID DERIVATIVE; CHEMOATTRACTANT; CYCLIC AMP; DICLOFENAC; G PROTEIN COUPLED RECEPTOR; INDOLE DERIVATIVE; INDOLEACETIC ACID; INDOMETACIN; INDOMETHACIN AMIDE; INDOMETHACIN METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RAMATROBAN; SEROTONIN; SULINDAC SULFIDE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZOMEPIRAC;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL MIGRATION; CELL STIMULATION; CELL STRAIN HEK293; CHEMOTAXIS; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BINDING; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL MOVEMENT; CYCLIC AMP; ECDYSTERONE; HUMANS; INDOMETHACIN; KIDNEY; MICE; PROSTAGLANDIN D2; RADIOLIGAND ASSAY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECOMBINANT PROTEINS; TRANSFECTION; TRITIUM;

EID: 14944363741     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.007971     Document Type: Article

References (40)

1. Audoly L and Breyer RM (1997) Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. Mol Pharmacol 51:61-68.
2. Barr RM, Koro O, Francis DM, Black AK, Numata T, and Greaves MW (1988) The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions. Br J Pharmacol 94:773-780.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Cost H, Gespach C, and Abita JP (1981) Effect of indomethacin on the binding of the chemotactic peptide formyl-Met-Leu-Phe on human polymorphonuclear leukocytes. FEBS Lett 132:85-88.
5. DeMartino JA, Konteatis ZD, Siciliano SJ, Van Riper G, Underwood DJ, Fischer PA, and Springer MS (1995) Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs. J Biol Chem 270:15966-15969.
6. Duggan DE, Hogans AF, Kwan KC, and McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181:563-575.
7. Furse KE and Lybrand TP (2003) Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J Med Chem 46:4450-4462.
8. Goldsmith MH (1993) Cellular signaling: new insights into the action of the plant growth hormone auxin. Proc Natl Acad Sci USA 90:11442-11445.
9. Hamid Q, Tulic MK, Liu MC, and Moqbel R (2003) Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol 111:S5-S12; discussion S12-S17.
10. Hata AN, Zent R, Breyer MD, and Breyer RM (2003) Expression and molecular pharmacology of the mouse CRTH2 Receptor. J Pharmacol Exp Ther 306:463-470.
11. 2 receptor. Biochem Biophys Res Commun 307:797-802.
12. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, and Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin D(2) receptor, CRTH2. J Immunol 168:981-985.
13. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255-261.
14. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, and Marnett LJ (2000a) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 97:925-930.
15. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, and Marnett LJ (2000b) Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43:2860-2870.
16. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410.
17. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, and Roberts LJ 2nd (1982) Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129:1627-1631.
18. Levering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, and White SA (2004) Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 64:1802-1810.
19. Mills JS, Miettinen HM, Cummings D, and Jesaitis AJ (2000) Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu. J Biol Chem 275:39012-39017.
20. Minta JO and Williams MD (1985) Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J Rheumatol 12:751-757.
21. Murray JJ, Tonnel AB, Brash AR, Roberts LJ, 2nd, Gosset P, Workman R, Capron A and Oates JA (1986) Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315:800-804.
22. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, Nakamura M, and Takano S (1999a) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 459:195-199.
23. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K, and Takano S (1999b) Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 162:1278-1286.
24. Narita S, Asakura K, and Kataura A (1996) Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol 109:161-166.
25. Negishi M, Irie A, Sugimoto Y, Namba T, and Ichikawa A (1995) Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of α-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem 270:16122-16127.
26. Perianin A, Gougerot-Pocidalo MA, Giroud JP, and Hakim J (1987) Diclofenac binding to human polymorphonuclear neutrophils: effect on respiratory burst and N-formylated peptide binding. Biochem Pharmacol 36:2609-2615.
27. Prusakiewicz JJ, Felts AS, Mackenzie BS, and Marnett LJ (2004) Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. Biochemistry 43:15439-15445
28. 2 receptor, CRTH2. Br J Pharmacol 137:1163-1172.
29. Shelly J and Hoff SF (1989) Effects of non-steroidal anti-inflammatory drugs on isolated human polymorphonuclear leukocytes (PMN): chemotaxis, superoxide production, degranulation and N-formyl-L-methionyl-L-leucyl-L- phenylalanine (FMLP) receptor binding. Gen Pharmacol 20:329-334.
30. Shen TY (1964) Synthesis and biological activity of some indomethacin analogs, in International Symposium on Non-Steroidal Anti-Inflammatory Drugs (Garattini S and Dukes MNG eds) pp 13-20, Excerpta Medica Foundation, Milan, Italy.
31. 2-induced eosinophilia in rats. J Pharmacol Exp Ther 307:518-525.
32. Skubitz KM and Hammerschmidt DE (1986) Effects of ibuprofen on chemotactic peptide-receptor binding and granulocyte response. Biochem Pharmacol 35:3349-3354.
33. 2-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem 277:26012-26020.
34. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, and Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305:347-352.
35. 2 receptor antagonists. Bioorg Med Chem Lett 14:4557-4562.
36. 2 receptor antagonists. Bioorg Med Chem 12:5361-5378.
37. 2 receptor antagonists. Bioorg Med Chem Lett 14:4891-4895.
38. Van Dyke K, Peden D, Van Dyke C, Jones G, Castranova V, and Ma J (1982) Inhibition by nonsteroidal antiinflammatory drugs of luminol-dependent human-granulocyte chemiluminescence and [3H]FMLP binding. Effect of sulindac sulfide, indomethacin metabolite and optical enantiomers (+) and (-) MK830. Inflammation 6:113-125.
39. Vree TB, van den Biggelaar-Martea M, and Verwey-van Wissen CP (1993) Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. J Chromatogr 616:271-282.
40. Zhang X, Morham SG, Langenbach R, and Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190:451-459.